Showing 1911-1920 of 8649 results for "".
- Staar Surgical and Kobe Kanagawa Eye Clinic in Japan Announce Strategic Cooperation Agreementhttps://modernod.com/news/staar-surgical-and-kobe-kanagawa-eye-clinic-in-japan-announce-strategic-cooperation-agreement/2480068/Staar Surgical and Kobe Kanagawa Eye Clinic, with locations in Tokyo and Osaka, announced they have entered into a multi-year Strategic Cooperation Agreement to provide Staar’s EVO Visian ICL lenses as a primary and premium option for patients seeking visual freedom from spectacles and cont
- New Company TearRestore Launches Reusable Heat Packs to Target the Meibomian Glandshttps://modernod.com/news/new-company-tearrestore-launches-reusable-heat-packs-to-target-the-meibomian-glands/2478355/New company TearRestore is seeking to simplify warm compress treatment by offering the proprietary TearRestore product. The product utilizes specially designed reusable heat packs to target the Meibomian glands while
- HelpMeSee Expands Simulation-based Cataract Surgery Training with New Partnerships at USC and UIChttps://modernod.com/news/helpmesee-expands-simulation-based-cataract-surgery-training-with-new-partnerships-at-usc-and-uic/2482623/HelpMeSee has announce its latest training partnerships with the University of Southern (USC)/LA General Medical Center in Los Angeles, and the University of Illinois Chicago (UIC). These collaborations establish two new
- Zeiss Introduces New Solution Enhancements for Procedure Workflows at ESCRS and Euretinahttps://modernod.com/news/zeiss-introduces-new-solution-enhancements-for-procedure-workflows-at-escrs-and-euretina/2478352/At the ESCRS virtual conference, Zeiss is presenting new solution enhancements aimed at helping doctors maximize clinical efficiency and improve patient care—from assessment, diagnosis, to treatment. Zeiss says the la
- Insurer Ducks Virus Coverage Claims From NJ Eye Practicehttps://modernod.com/news/insurer-ducks-virus-coverage-claims-from-nj-eye-practice/2478857/A proposed class action lawsuit from an eye clinic in New Jersey, which was seeking to recoup losses it incurred during the COVID-19 pandemic from an insurance company, was struck down by a New Jersey federal judge, according to a LAW360
- Yuyu Pharma Announces Topline Results from the ICECAP Phase 1/2 Trial of YP-P10 in Dry Eye Diseasehttps://modernod.com/news/yuyu-pharma-announces-topline-results-from-the-icecap-phase-12-trial-of-yp-p10-in-dry-eye-disease/2481651/Yuyu Pharma announced topline results from the ICECAP phase 1/2 trial of YP-P10 in patients with dry eye disease. ICECAP was the first human, signal-seeking, phase 1/2 trial evaluating the safety and efficacy of YP-P10 over 12 weeks (85 days) of treatment in subjects with dry eye disease, ac
- HHS Bids $250 Million Contract Meant to ‘Defeat Despair and Inspire Hope’ on Coronavirushttps://modernod.com/news/hhs-bids-250-million-contract-meant-to-defeat-despair-and-inspire-hope-on-coronavirus/2478236/As the presidential election fast approaches, the Department of Health and Human Services is bidding out a more than $250 million contract to a communications firm as it seeks to “defeat despair and inspire hope” about the coronavirus pandemic, according to a
- FBI and DHS Warn that Chinese Hackers Are Targeting US COVID Researchhttps://modernod.com/news/fbi-and-dhs-warn-that-chinese-hackers-are-targeting-us-covid-research/2477761/Cyber actors and “non-traditional collectors” linked to the Chinese government are targeting and possibly seeking to compromise U.S. organizations conducting COVID-19 research, two U.S. security agencies warned, according to a CBS
- Ocular Therapeutix Submits Supplemental NDA for Dextenza for the Treatment of Postoperative Inflammationhttps://modernod.com/news/ocular-therapeutix-submits-supplemental-nda-for-dextenza-for-the-treatment-of-postoperative-inflammation/2476198/Ocular Therapeutix announced the submission of a supplemental new drug application (NDA) to the FDA for Dextenza (dexamethasone ophthalmic insert). The sNDA filing seeks to expand the current indication for Dextenza to include the treatment of ocular inflammation following ophthalmic surgery. The
- Smartlens Secures $5.2 Million to Advance FDA Clearance and Commercial Launch of miLenshttps://modernod.com/news/smartlens-secures-52-million-to-advance-fda-clearance-and-commercial-launch-of-milens/2484291/Smartlens announced the closing of an oversubscribed $5.2 million bridge financing round to accelerate the company’s FDA clearance process and support preparations for an expedited U.S. market launch of its flagship product, miLens, f